other material
confidence high
sentiment positive
materiality 0.85
Intellia reports positive lonvo-z HAE data: 97% attack-free; nex-z shows 87% TTR reduction at 36 months
Intellia Therapeutics, Inc.
- Lonvo-z pooled Phase 1/2: 97% (31/32) attack-free and LTP-free; 75% attack-free for ≥7 months (up to 32 months).
- Mean kallikrein reduction 89% at month 24; well-tolerated safety up to 3 years with no long-term risks.
- Nex-z Phase 1: 87% mean serum TTR reduction at 36 months (n=9); all-cause mortality rate 3.9 vs 12.7 per 100 patient-years (HR 0.27, p=0.009) vs matched cohort.
- Nex-z showed disease stability or improvement on multiple cardiomyopathy markers at 24 months; 81% stable/improved NYHA class.
- FDA clinical hold on nex-z Phase 3 MAGNITUDE/MAGNITUDE-2 trials; company working to address.